Compare CNX & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNX | CRSP |
|---|---|---|
| Founded | 1860 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.7B |
| IPO Year | 1998 | 2016 |
| Metric | CNX | CRSP |
|---|---|---|
| Price | $41.90 | $60.29 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 9 | 17 |
| Target Price | $35.78 | ★ $70.00 |
| AVG Volume (30 Days) | ★ 2.1M | 1.5M |
| Earning Date | 04-30-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 763.33 | N/A |
| EPS | ★ 3.98 | N/A |
| Revenue | ★ $2,239,134,000.00 | $289,590,000.00 |
| Revenue This Year | $0.03 | $1,603.19 |
| Revenue Next Year | $9.44 | $78.75 |
| P/E Ratio | $10.48 | ★ N/A |
| Revenue Growth | 76.76 | ★ 9169.85 |
| 52 Week Low | $27.68 | $30.06 |
| 52 Week High | $43.12 | $78.48 |
| Indicator | CNX | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 63.15 | 59.60 |
| Support Level | $36.33 | $51.64 |
| Resistance Level | N/A | $60.40 |
| Average True Range (ATR) | 1.55 | 3.18 |
| MACD | 0.20 | 0.90 |
| Stochastic Oscillator | 80.64 | 87.86 |
CNX Resources Corp is an independent low carbon intensity natural gas and midstream company engaged in the exploration, development, production and acquisition of natural gas properties in the Appalachian Basin. The company's operating segment include Shale and Coalbed Methane. It generates maximum revenue from the Shale segment. It also has other segment that includes nominal shallow oil and gas production.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.